0001209191-21-010517.txt : 20210212
0001209191-21-010517.hdr.sgml : 20210212
20210212212843
ACCESSION NUMBER: 0001209191-21-010517
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210210
FILED AS OF DATE: 20210212
DATE AS OF CHANGE: 20210212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOUMEAU ERIC J
CENTRAL INDEX KEY: 0001239648
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 21631557
MAIL ADDRESS:
STREET 1: C/O HOLLIS-EDEN PHARMACEUTICALS
STREET 2: 4435 EASTGATE MALL STE.400
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO, INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYSBIO INC
DATE OF NAME CHANGE: 20080828
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-10
0
0001370053
ANAPTYSBIO, INC
ANAB
0001239648
LOUMEAU ERIC J
C/O ANAPTYSBIO, INC.
10421 PACIFIC CENTER COURT, SUITE 200
SAN DIEGO
CA
92121
0
1
0
0
COO, General Counsel
Common Stock
2021-02-12
4
M
0
10000
14.02
A
10000
D
Common Stock
2021-02-12
4
S
0
10000
35.00
D
0
D
Stock Option (right to buy)
29.70
2021-02-10
4
A
0
45000
0.00
A
2031-02-09
Common Stock
45000
45000
D
Stock Option (right to buy)
14.02
2021-02-12
4
M
0
10000
0.00
D
2029-12-08
Common Stock
10000
88000
D
The transaction reported on this Form 4 were effected pursuant to a Rule 105b-1 trading plan adopted by the reporting person.
The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
The stock option vested as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
In addition to the remaining option to purchase 88,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 147,500 shares of common stock, which options vest according to their terms.
/s/ Eric Loumeau
2021-02-12